These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27494417)

  • 1. Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
    Gill D; Hahn AW; Sonpavde G; Agarwal N
    Hum Vaccin Immunother; 2016 Dec; 12(12):2997-3004. PubMed ID: 27494417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
    Weinstock M; McDermott DF
    Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in immunotherapy for kidney cancer.
    Ball MW; Allaf ME; Drake CG
    Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
    Grünwald V
    Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
    Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
    Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
    Liu KG; Gupta S; Goel S
    Oncotarget; 2017 Mar; 8(10):17313-17327. PubMed ID: 28061473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
    Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
    Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of available treatment options for renal cell carcinoma.
    Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
    Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do immune-related adverse events correlate with response to immune checkpoint inhibitors?
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
    Thomas JS; Kabbinavar F
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New immunotherapy in the treatment of advanced renal cancer.
    Muto A; Gridelli C
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):233-237. PubMed ID: 31751164
    [No Abstract]   [Full Text] [Related]  

  • 15. [Renaissance of immuno-oncology for urological tumors : Current status].
    Grimm MO; Winkler Y; Fetter I; Oppel-Heuchel H
    Urologe A; 2016 May; 55(5):621-6. PubMed ID: 27119960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in kidney cancer: the past, present, and future.
    Hammers H
    Curr Opin Urol; 2016 Nov; 26(6):543-7. PubMed ID: 27533501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
    Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
    Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
    Oppel-Heuchel H; Grimm MO
    Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk-adapted (immuno)therapy for renal cell carcinoma].
    Grünwald V
    Urologe A; 2018 Nov; 57(11):1326-1333. PubMed ID: 30350129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.